ALX Oncology Holdings Financial Statements (ALXO)
|
|
|
|
Report date
|
|
|
28.02.2022 |
09.03.2023 |
07.03.2024 |
06.03.2025 |
09.03.2026 |
|
09.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-83.6 |
-127.4 |
-170.3 |
-142.5 |
-100.8 |
|
-104.0 |
|
EBITDA, bln rub |
? |
|
-83.4 |
-122.8 |
-158.4 |
-132.2 |
-100.8 |
|
-100.1 |
|
Net profit, bln rub |
? |
|
-83.5 |
-123.5 |
-160.8 |
-134.9 |
-101.7 |
|
-101.7 |
|
|
OCF, bln rub |
? |
|
-68.1 |
-89.2 |
-130.4 |
-121.9 |
-84.1 |
|
-84.1 |
|
CAPEX, bln rub |
? |
|
4.92 |
1.43 |
1.27 |
0.447 |
0.212 |
|
0.212 |
|
FCF, bln rub |
? |
|
-73.0 |
-90.7 |
-131.6 |
-122.4 |
-84.4 |
|
-84.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
83.6 |
127.4 |
170.3 |
142.5 |
100.8 |
|
104.0 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
R&D, bln rub |
|
|
60.2 |
98.4 |
141.8 |
116.4 |
77.0 |
|
77.0 |
|
Interest expenses, bln rub |
|
|
0.013 |
0.238 |
1.57 |
1.73 |
1.60 |
|
1.60 |
|
|
Assets, bln rub |
|
|
380.2 |
306.5 |
242.6 |
147.8 |
59.0 |
|
59.0 |
|
Net Assets, bln rub |
? |
|
363.0 |
263.5 |
189.7 |
113.6 |
26.0 |
|
26.0 |
|
Debt, bln rub |
|
|
0.742 |
10.4 |
17.2 |
17.0 |
5.22 |
|
5.22 |
|
Cash, bln rub |
|
|
363.7 |
266.2 |
182.7 |
127.8 |
44.8 |
|
44.8 |
|
Net debt, bln rub |
|
|
-362.9 |
-255.8 |
-165.5 |
-110.8 |
-39.6 |
|
-39.6 |
|
|
Ordinary share price, rub |
|
|
21.5 |
11.3 |
14.9 |
1.67 |
1.13 |
|
7.70 |
|
Number of ordinary shares, mln |
|
|
40.3 |
40.7 |
43.0 |
52.2 |
53.7 |
|
54.3 |
|
|
Market cap, bln rub |
|
|
866 |
459 |
640 |
87 |
61 |
|
418 |
|
EV, bln rub |
? |
|
503 |
203 |
475 |
-24 |
21 |
|
378 |
|
Book value, bln rub |
|
|
363 |
263 |
190 |
114 |
26 |
|
26 |
|
|
EPS, rub |
? |
|
-2.07 |
-3.03 |
-3.74 |
-2.58 |
-1.90 |
|
-1.87 |
|
FCF/share, rub |
|
|
-1.81 |
-2.23 |
-3.06 |
-2.35 |
-1.57 |
|
-1.55 |
|
BV/share, rub |
|
|
9.01 |
6.47 |
4.41 |
2.18 |
0.48 |
|
0.48 |
|
|
FCF yield, % |
? |
|
-8.43% |
-19.8% |
-20.6% |
-140.4% |
-139.1% |
|
-20.2% |
|
ROE, % |
? |
|
-23.0% |
-46.9% |
-84.8% |
-118.7% |
-391.4% |
|
-391.4% |
|
ROA, % |
? |
|
-22.0% |
-40.3% |
-66.3% |
-91.3% |
-172.2% |
|
-172.2% |
|
|
P/E |
? |
|
-10.4 |
-3.71 |
-3.98 |
-0.65 |
-0.60 |
|
-4.11 |
|
P/FCF |
|
|
-11.9 |
-5.06 |
-4.86 |
-0.71 |
-0.72 |
|
-4.96 |
|
P/BV |
? |
|
2.39 |
1.74 |
3.37 |
0.77 |
2.33 |
|
16.1 |
|
EV/EBITDA |
? |
|
-6.03 |
-1.65 |
-3.00 |
0.18 |
-0.21 |
|
-3.78 |
|
Debt/EBITDA |
|
|
4.35 |
2.08 |
1.05 |
0.84 |
0.39 |
|
0.40 |
|
|
R&D/CAPEX, % |
|
|
1 222% |
6 896% |
11 130% |
26 034% |
36 319% |
|
36 319% |
|
| ALX Oncology Holdings shareholders |
